PMI Science Poster Discussion Symposium

      Date
      Jun 24, 2015 - Jun 24, 2015
      Location
      International Convention Center Jeju, 2700 Jungmun-dong, Seogwipo-s, Jeju-do, South Korea
      PMIScience are organizing a Scientific Poster Discussion Symposium on the 24th June 2015 at the International Convention Centre, Jeju, South Korea and we would like to you to take part in this exciting event! This symposium is an opportunity for us to share our latest science in the field of Tobacco Harm Reduction and have an open and fruitful discussion with you on our scientific approach. Our Symposium will include all of the posters we are presenting at the 2015 AsiaTox meeting, and will give us the opportunity to have an in-depth discussion and hear your views on the science presented. At the symposium we will also discuss how the science presented fits into our overall approach for developing and assessing reduced risk tobacco products.  You can find the agenda for the meeting below, which details all of the posters that we will be presenting.  The format of the meeting allows for a free-poster session at the beginning of the symposium, followed by a key-note presentation by Dr Manuel Peitsch. This will be followed by a 10-minute presentation and discussion of each poster. You can receive your complimentary invitation to this symposium by filling in the registration form before the 17th June 2015. Thank you and we look forward to welcoming you to the PMI Science Poster Discussion Symposium.   7:00 – 7:30 PM     Open poster session   7:30 – 7:40 PM     Welcome & Overview By Manuel Peitsch, Vice President Biological Systems Research              7:40 – 7:45 PM     Introduction to poster discussion By Nveed Chaudhary, Manager Scientific Engagement              7:45 – 9:25 PM     Poster presentations and discussion 1) Cardiovascular and respiratory endpoints from ApoE-/- mice showed similar effects after switching to a candidate modified risk tobacco product or to smoking cessation. (Blaine Philips) 2) Systems toxicology analysis of respiratory endpoints from ApoE-/- mice showed similar effects after switching to a candidate modified risk tobacco product, THS 2.2, or to smoking cessation. (Ashraf Elamin) 3) The effects of cigarette smoke exposure on vascular reperfusion and recovery of ApoE -/- mice following unilateral hind limb ischemia. (Julia Hoeng) 4) Modeling transport and evolution of aerosols for accurate predictions of local deposition in an in-vitro exposure system. (Markus Nordlund) 5) Deposition of mono-disperse glycerin-based aerosol in a realistic cast of a human respiratory tract. (Markus Nordlund) 6) Systems toxicology assessment of nutraceuticals in human primary hepatocytes and coronary artery endothelial cells. (Ignacio Gonzalez-Suarez) 7) Systems Toxicology-based assessment of a candidate Reduced Risk Product using Human Organotypic Tissue Cultures of Nasal and Bronchial Epithelium. (Carole Mathis) 8) Indoor Air Chemistry: comparative study between conventional cigarette and heat-not-burn technology. (Moira Gilchrist) 9) Pharmacokinetics of nicotine and subjective effects following the single use of a non-menthol and menthol version of Tobacco Heating System 2.2 in two studies in japan: A comparison with single use of a combustible cigarette and nicotine gum. (Nveed Chaudhary) 10) Reduced Exposure to Harmful and Potentially Harmful Constituents after five days of use of Tobacco Heating System 2.2: A comparison with continued combustible cigarette use or smoking abstinence [Japan]. (Nveed Chaudhary) 9:25 – 9:30 PM     Wrap-up & Closure By Nveed Chaudhary, Manager Scientific Engagement

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.